Item Type | Name |
Concept
|
Factor V
|
Concept
|
Factor X
|
Concept
|
Factor XI
|
Concept
|
Factor Xa Inhibitors
|
Concept
|
Factor VIIa
|
Concept
|
Factor XIa
|
Concept
|
Factor Xa
|
Academic Article
|
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
|
Academic Article
|
Oral rivaroxaban for symptomatic venous thromboembolism.
|
Academic Article
|
Apixaban for extended treatment of venous thromboembolism.
|
Academic Article
|
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.
|
Academic Article
|
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
|
Academic Article
|
Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
|
Academic Article
|
Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients.
|
Academic Article
|
Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study.
|
Academic Article
|
Effect of treatment with low-dose warfarin-aspirin on activated factor VII.
|
Academic Article
|
Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement.
|
Academic Article
|
Extended prophylaxis of venous thromboembolism with idraparinux.
|
Academic Article
|
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
|
Academic Article
|
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
|
Academic Article
|
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
|
Academic Article
|
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
|
Academic Article
|
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
|
Academic Article
|
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
|
Academic Article
|
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.
|
Academic Article
|
Edoxaban for Cancer-Associated Venous Thromboembolism.
|
Academic Article
|
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
|
Academic Article
|
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.
|
Academic Article
|
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
|
Academic Article
|
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
|
Academic Article
|
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.
|
Academic Article
|
Oral apixaban for the treatment of acute venous thromboembolism.
|
Academic Article
|
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
|
Academic Article
|
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
|
Academic Article
|
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
|
Academic Article
|
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
|
Academic Article
|
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
|
Academic Article
|
Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
|
Academic Article
|
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
|
Academic Article
|
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
|
Academic Article
|
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
|
Academic Article
|
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.
|
Academic Article
|
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
|
Academic Article
|
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists.
|
Academic Article
|
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
|
Academic Article
|
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
|
Academic Article
|
Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.
|
Academic Article
|
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
|
Academic Article
|
Duration of anticoagulant treatment for venous thrombosis.
|
Grant
|
THROMBOSIS: ETIOLOGY, RISK FACTORS AND TREATMENT
|
Academic Article
|
Milvexian for the Prevention of Venous Thromboembolism.
|
Academic Article
|
Abelacimab for Prevention of Venous Thromboembolism.
|
Academic Article
|
Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis.
|
Academic Article
|
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban.
|